Dipeptidyl Peptidase-4 Inhibitors May Up Pancreatic Disease Risk
WEDNESDAY, Aug. 28, 2019 -- Use of dipeptidyl peptidase-4 inhibitors (DPP-4i) is associated with increased risks for pancreatitis and pancreatic cancer in patients with newly diagnosed type 2 diabetes, according to a study published online Aug. 20 in Diabetes Care.
Minyoung Lee, M.D., from the Yonsei University College of Medicine in Seoul, South Korea, and colleagues used the Korean National Health Insurance Service-Health Screening Cohort database to identify 33,208 patients with newly diagnosed type 2 diabetes who were treated with antidiabetes drugs from 2007 to 2013. Associations between DPP-4i and pancreatitis and pancreatic cancer were investigated.
The researchers found that 10,218 patients were new users of DPP-4i and 22,990 were new users of other antidiabetes drugs. There were significantly increased risks for pancreatitis (adjusted hazard ratio, 1.24) and pancreatic cancer (adjusted hazard ratio, 1.81) with DPP-4i. There was a six-month drug use lag period. Within the first 12 months and one year after the initial prescription, the risk for pancreatitis and pancreatic cancer was generally consistent without showing an increasing trend according to exposure duration.
"The absence of increasing trend according to exposure duration suggests the chances of reverse causality, and long-term pancreatic safety of DPP-4i has to be further investigated," the authors write.
© 2020 HealthDay. All rights reserved.
Posted: August 2019
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.